All issues

Regulatory

EMA, national regulators, the EU Clinical Trials Regulation and guidance in development.

10 issues

• 2026-09-29No. 16

  Initiated in Q2. Unregistered at the end of Q3.

  • TRIALS
  • DEALS
  • REGULATORY
  • LILLY
  • ATAIBECKLEY
  • COMPASS
  • CYBIN
• 2026-09-22No. 15

  The CVR is an option, and Lilly holds it

  • DEALS
  • REGULATORY
  • TRIALS
  • LILLY
  • ATAIBECKLEY
  • COMPASS
  • ABBVIE
  • OTSUKA
• 2026-09-15No. 14

  Five countries, one regulator.

  • TRIALS
  • DEALS
  • REGULATORY
  • DEFINIUM
  • LILLY
  • ATAIBECKLEY
  • COMPASS
  • GH
• 2026-09-08No. 13

  Three authorised, one counted.

  • TRIALS
  • REGULATORY
  • SLAGELSE
  • CHIETI
  • AMSTERDAM-UMC
  • ARQ
  • DEFINIUM
• 2026-09-01No. 12

  Lilly’s depression trial went from one approval to four in seven days.

  • TRIALS
  • REGULATORY
  • LILLY
  • ATAIBECKLEY
  • ATAI-THERAPEUTICS
• 2026-08-25No. 11

  Lilly has five authorised trials in the EU system. None of them are the drugs it just bought.

  • TRIALS
  • REGULATORY
  • LILLY
  • ATAIBECKLEY
  • BECKLEY-PSYTECH
  • REGION-SKANE
• 2026-08-18No. 10

  A clinician, not a company, runs Germany's psilocybin compassionate use programme

  • ACCESS
  • REGULATORY
• 2026-08-04No. 9

  No European application on file for the world's most advanced psilocybin programme

  • REGULATORY
  • ACCESS
  • COMPASS
• 2026-07-28No. 8

  Europe already pays for clinic-administered psychiatry. Just not for psychedelics.

  • ACCESS
  • REGULATORY
• 2026-07-21No. 7

  Eli Lilly buys AtaiBeckley for $3.8B, and prices Europe out of psychedelic medicine

  • DEALS
  • REGULATORY
  • LILLY
  • ATAIBECKLEY